Back from the Brink

October 7, 2022 |
“Evidence” & “Time” As Obstacles In The Waiver Route For Drugs And Tests For COVID-19 At The WTO
Novartis agrees to license a best-selling cancer drug to dozens of low- and middle-income countries
Related Posts
Access to Medicines

Pharma’s alleged “brea...
PEPFAR Watch

PEPFAR is Rolling the Cloc...
Access to Medicines

Pharma Pricing Secrecy Run...